Molly®
Molly® is a single-dose autoinjector technology developed to help pharma and biotech companies reduce initial investments and expedite development timelines.
Meet Molly®
Meet all requirements
Built on a modular platform technology, Molly® is designed to meet the evolving requirements of future autoinjectors, such as introducing unique designs for branding and user requirements, as well as high-volume manufacturing.
The Molly autoinjector is designed with an ergonomic body and a flange-shaped anti-roll cap for an easier handling experience.
Specifications
- Viscosity
- low
- Volume
- 1.0 ml
- Device type
- Disposable autoinjector
- Primary container
- Pre-Filled Syringe
- Route of administration
- Subcutaneous
- Connectivity
- Yes
- Dosage type
- Fixed | Full contents
- Activation method
- Needle cover
- Injection feedback
- Audible click, viewing window
- Customization
- Yes
Unparalleled track record
We work with 12+ pharmaceutical companies to commercialize our Molly® and Molly® 2.25 autoinjectors. 17 combination products have been approved so far, including the world’s first large-volume autoinjector with a ≥ 2.0 mL fill.
Rheumatoid arthritis
Six years after introducing the Molly® platform, our first Molly® autoinjector was launched in 2016, treating moderate to severe rheumatoid arthritis.
Migraine
In 2016, the second Molly® autoinjector was launched, specifically designed for a medication targeting acute migraine headaches.
Atopic dermatitis
Molly® and Molly® 2.25 were introduced in 2020 as treatments for asthma and atopic dermatitis.
Diabetes
In 2020, the Molly® autoinjector was launched as a self-injection option for diabetes patients, designed to complement insulin therapy.
Hypoglycemia
In 2019, we launched the Molly® autoinjector to treat severe hypoglycemia (very low blood sugar) in adults and children aged 2 years and older with diabetes.
Weight management
Launched in 2021, SHL Medical's Molly® autoinjector is used for effective weight-loss treatments, significantly impacting the pharmaceutical industry and patient care.
Want to check if Molly® is suitable for your molecular entity? Get in touch.
Modular platform technology
Molly®'s modular autoinjector platform technology takes a unique approach to platform design by integrating modules into its ecosystem. These modules refer to the Molly device design and core technology, manufacturing infrastructures, and add-on features that respond to digital health and sustainability imperatives, as well as the ever-changing market landscape.
Other variations
Molly® 2.25
Molly® 2.25 is a large-volume variant of the Molly autoinjector to accommodate larger-volume biologics. Featuring the same easy-to-use, 2-step operation, it inherited the modular platform development model to support high-volume manufacturing, faster development, and flexible design for unique branding needs.
Molly® Connected Cap
Upon removal from the Molly® device, the Connected Cap becomes active, allowing timestamped data to be relayed through a smart data transmission hub and to the cloud.